Z. Euler

发表

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

Michael S. Seaman, Yan Liu, Pamela J. Bjorkman, 2012, Proceedings of the National Academy of Sciences.

Cross-reactive broadly neutralizing antibodies: timing is everything

H. Schuitemaker, Z. Euler, 2012, Front. Immun..

Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users

Todd M. Allen, A. Trkola, T. Allen, 2019, Viruses.

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression

H. Schuitemaker, T. Wrin, B. Schweighardt, 2009, AIDS.

Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals

H. Schuitemaker, M. V. van Gils, Z. Euler, 2013, PloS one.

Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer

G. Meijer, E. Bloemena, H. van Tinteren, 2011, Clinical Cancer Research.

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

E. Bunnik, H. Schuitemaker, T. Wrin, 2010, The Journal of infectious diseases.

Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity

H. Schuitemaker, T. Wrin, M. V. van Gils, 2011, Journal of Virology.

Broadly reactive neutralizing activity in HIV-1 infected injecting drug users

Todd M. Allen, H. Schuitemaker, R. Sanders, 2016 .

Blimp-1, an Intrinsic Factor that Represses HIV-1 Proviral Transcription in Memory CD4+ T Cells

G. Alter, Malini Natarajan, Z. Euler, 2015, The Journal of Immunology.

current as T Cells + CD 4 HIV-1 Proviral Transcription in Memory Blimp-1 , an Intrinsic Factor that Represses

G. Alter, Malini Natarajan, Z. Euler, 2015 .

Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers

H. Schuitemaker, R. Sanders, M. V. van Gils, 2014, AIDS.

HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity

Jaap Heringa, K Anton Feenstra, Hanneke Schuitemaker, 2013, Retrovirology.

Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

G. Alter, Z. Euler, 2015, AIDS research and human retroviruses.

HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound.

Todd M. Allen, D. Lauffenburger, M. Altfeld, 2020, Cell reports.

Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)

Galit Alter, David C Montefiori, Nigel Garrett, 2018, The Lancet.

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

J. Kublin, D. Montefiori, H. Schuitemaker, 2020, The lancet. HIV.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

Jennifer A. Johnson, B. Korber, P. Earl, 2018, The Journal of infectious diseases.

Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level

E. Bunnik, H. Schuitemaker, J. Prins, 2010, Nature Medicine.

The Development of CD4 Binding Site Antibodies during HIV-1 Infection

B. Haynes, J. Mascola, R. Dersimonian, 2012, Journal of Virology.

The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype.

H. Schuitemaker, N. Kootstra, R. Sanders, 2016, AIDS research and human retroviruses.

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies

D. Burton, H. Schuitemaker, T. Wrin, 2015, PLoS pathogens.

Activity of Broadly Neutralizing Antibodies, Including PG9, PG16, and VRC01, against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Epidemic

E. Bunnik, H. Schuitemaker, J. Prins, 2011, Journal of Virology.

against recently transmitted subtype B HIV-1 variants from early and late in the 2

E. Bunnik, H. Schuitemaker, J. Prins, 2011 .

Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection.

G. Alter, T. Henrich, E. Scully, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011

R. Shattock, B. Wahrén, G. Scarlatti, 2012, Journal of Translational Medicine.

Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies

B. Walker, T. Ndung’u, L. Morris, 2017, Front. Immunol..

P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level

H. Schuitemaker, M. Welkers, Z. Euler, 2009, Retrovirology.

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.

E. Bunnik, H. Schuitemaker, T. Wrin, 2010, The Journal of infectious diseases.

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression

H. Schuitemaker, T. Wrin, B. Schweighardt, 2009, AIDS.

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011

R. Shattock, G. Scarlatti, F. Fiorino, 2012, Journal of Translational Medicine.

HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals

H. Schuitemaker, Z. Euler, B. Boeser-Nunnink, 2012, Retrovirology.